XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 212 filers reported holding XENON PHARMACEUTICALS INC in Q2 2024. The put-call ratio across all filers is 1.02 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $640,060 | -52.5% | 16,416 | -47.5% | 0.00% | -60.0% |
| Q1 2024 | $1,346,604 | +87.6% | 31,280 | +100.7% | 0.01% | +66.7% |
| Q4 2023 | $717,799 | +80.8% | 15,584 | +34.1% | 0.00% | +50.0% |
| Q3 2023 | $397,042 | +12.2% | 11,623 | +26.4% | 0.00% | 0.0% |
| Q2 2023 | $353,931 | +6.3% | 9,193 | -1.2% | 0.00% | 0.0% |
| Q1 2023 | $333,098 | -10.5% | 9,307 | -1.4% | 0.00% | 0.0% |
| Q4 2022 | $372,180 | +54.4% | 9,439 | +41.6% | 0.00% | +100.0% |
| Q3 2022 | $241,000 | +18.7% | 6,667 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $203,000 | -1.5% | 6,667 | -1.0% | 0.00% | 0.0% |
| Q1 2022 | $206,000 | -31.1% | 6,733 | -29.6% | 0.00% | 0.0% |
| Q4 2021 | $299,000 | +367.2% | 9,565 | +127.7% | 0.00% | – |
| Q3 2021 | $64,000 | -15.8% | 4,201 | +2.7% | 0.00% | – |
| Q2 2021 | $76,000 | +4.1% | 4,091 | 0.0% | 0.00% | – |
| Q1 2021 | $73,000 | – | 4,091 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 3,516,851 | $44,101,000 | 2.72% |
| Parkman Healthcare Partners LLC | 590,267 | $7,402,000 | 2.08% |
| ACUTA CAPITAL PARTNERS, LLC | 517,500 | $6,489,000 | 1.88% |
| Soleus Capital Management, L.P. | 250,897 | $3,146,000 | 1.79% |
| DAFNA Capital Management LLC | 346,535 | $4,346,000 | 1.25% |
| KNOTT DAVID M | 169,000 | $2,119,000 | 1.16% |
| Ghost Tree Capital, LLC | 325,000 | $4,076,000 | 1.08% |
| Avoro Capital Advisors LLC | 2,800,000 | $35,112,000 | 0.69% |
| NEA Management Company, LLC | 992,107 | $12,441,000 | 0.50% |
| Orbimed Advisors | 2,497,917 | $31,324,000 | 0.44% |